Flexion Therapeutics Inc (FLXN) News

Let's go Brandon

Just In: $FLXN Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million

BURLINGTON, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of $23.6 million for the quarter ended September 30, 2020. “We are ...

Find out more FLXN - Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million

News: $FLXN Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales

Company reported ZILRETTA  ( triamcinolone acetonide extended-release injectable suspension) preliminary net sales of $15.4 million in the second quarter Demand for ZILRETTA from healthcare providers increased month-over-month throughout the second quarter with t...

In case you are interested FLXN - Flexion Therapeutics Announces Preliminary Second-Quarter 2020 ZILRETTA® Net Sales

News: $FLXN Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® (triamcinolone acetonide extended-release injectable suspension)

Pooled analysis published in Pain and Therapy indicated that the number of rescue medication tablets used per day through Week 24 was significantly less for ZILRETTA versus placebo and triamcinolone acetonide crystalline suspension (TAcs) Reduced rescue medication use further supports ...

Find out more https://marketwirenews.com/news-releases/flexion-therapeutics-announces-publication-of-pooled-analysis-of-phase-2-3-data-on-use-of-rescue-medication-with-zilretta-xae-triamcinolone-acetonide-extended-release-injectable-suspension--8159442.html

News: $FLXN Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer

BURLINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the company’s Senior Vice President...

Got this from https://marketwirenews.com/news-releases/flexion-therapeutics-names-christina-willwerth-chief-strategy-officer-7449860.html

http://www.otcmarkets.com/stock/FLXN

http://www.stockscores.com/charts/charts/?ticker=FLXN

bought more

http://www.barchart.com/detailedquote/stocks/FLXN

Flexion Therapeutics (FLXN)
23.41 ? 0.74 (3.26%)
Volume: 721,523 @ 5:04:31 PM EST ET
Bid Ask Day's Range
22.75 24.6 22.71 - 23.4655
FLXN Detailed Quote

http://www.barchart.com/opinions/stocks/FLXN

Any updates/thoughts from your former colleagues would be interesting to hear.

I just spoke with two recently hired FLXN sales reps. I worked with both at a previous pharma co. They are both very talented reps and have tremendous launch experience. They’ll be out in the field on 11/20!!! Hopefully the rest of the field sales force is just as talented.

Added some here at 20.51 crazy....!

23.65 almost 2 points below the recent offering.

Took a starter position here.

When will you buy in again?

im buying at the lower level., buy out rumor coming soon

Classic case of sell on the news, but I do think we reach $40 by years end

$FLXN should be flying with approval of billion dollar drug.

https://www.stockscores.com/charts/charts/?ticker=FLXN

yea me 2 got in right b4 the halt looking 4 4o a share 2

Really unfortunate timing for that news to break at 3:00 Friday afternoon. Hoping for $40+ Monday

i bought in right b 4 the halt... whew

Flexion Therapeutics (FLXN)
24.64 ? -0.89 (-3.49%)
Volume: 305,691 @ 11:21:46 AM EDT ET
Bid Ask Day's Range
24.58 24.67 24.35 - 25.71
FLXN Detailed Quote

I would have thought we would be higher by this point!

Flexion Therapeutics (FLXN)
22.16 ? 0.0 (0.00%)
Volume: 10 @ 8:14:20 AM ET
Bid Ask Day's Range
20.5 23.5 - - -
FLXN Detailed Quote

FLXN News: Flexion to Present New Cost-Effectiveness Data on Zilretta™ (FX006) at the International Society for Pharmacoeconomics and ... 05/22/2017 07:30:00 AM
FLXN News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/19/2017 04:36:36 PM
FLXN News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/19/2017 04:34:25 PM
FLXN News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/19/2017 04:33:08 PM
FLXN News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/19/2017 04:30:05 PM

Flexion Therapeutics (FLXN)
19.59 ? 0.0 (0.00%)
Volume: 0 @- ET
Bid Ask Day's Range
17.44 21.56 - - -
FLXN Detailed Quote

Pfizer, Inc. (PFE)
34.1 ? -0.01 (-0.03%)
Volume: 13,973,510 @ 7:43:30 PM ET
Bid Ask Day's Range
- - 34.04 - 34.25
PFE Detailed Quote

Flexion Therapeutics (FLXN)
26.42 ? -0.67 (-2.47%)
Volume: 649,230 @ 4:28:58 PM ET
Bid Ask Day's Range
25.5 27.65 25.55 - 27.25
FLXN Detailed Quote

FLXN RSI 5

*****END OF 2016
CASH = 210 M
BURN RATE = 70M
BURN RATE = 7 M / MONTH

I got no position - Goodluck!

I see. 2nd round of shorting $27.15 thanks for whoever covered.

40% move on an address change.....wow people must be hungry for rumors. If news does break, it's already built into the share price $27+.

SNY Prescription Products ABOUT 34

http://www.sanofi.us/l/us/en/layout.jsp?scat=5668F5DC-416D-4978-A1B6-989FEE5957CB

https://www.thestreet.com/story/14057110/1/sanofi-nearing-1-billion-deal-for-flexion.html

Some sort of merger in the works

Flexion Therapeutics, Inc. 10 Mall Road Suite 301 Burlington, MA 01803 United States Phone: 781-305-7777 Fax: 781-202-3399 Website: http://www.flexiontherapeutics.com Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts

FLXN:
1. sells for 800 million more than its cash level
2. services an unmet need for people who are in for a lifetime of chronic pain
3. a nominal short interest


from DownWithPumpers

Today's vol is already at 1/2 the float.

Holders of Record

As of March 2, 2017, there were approximately 25 stockholders of record of our common stock. Certain shares are held in “street” name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.

Float 15.4 mil

Shares Outstanding (mil) = 31.7

EPS = -2.84

FLXN DAILY

Short $28

+40% on No filings? Looks like a PND.

FLXN News: Amended Statement of Ownership (sc 13g/a) 02/16/2017 02:01:39 PM

FLXN News: Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 02/15/2017 09:00:00 AM

FLXN News: Amended Statement of Ownership (sc 13g/a) 02/14/2017 08:06:48 AM